Navigation Links
Humana and Walmart Announce Innovative Medicare Part D Prescription Drug Plan with Lowest National Monthly Premium Offered in all 50 States and D.C. (1)
Date:9/30/2010

ts and a better health plan experience throughout its diversified customer portfolio.

More information regarding Humana is available to investors via the Investor Relations page of the company's Web site at http://www.humana.com, including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases
  • Replays of most recent earnings release conference calls
  • Calendar of events (includes upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
  • Corporate Governance Information

About Walmart

Wal-Mart Stores, Inc. (NYSE: WMT), or "Walmart," serves customers and members more than 200 million times per week at more than 8,400 retail units under 55 different banners in 15 countries. With fiscal year 2010 sales of $405 billion, Walmart employs more than 2 million associates worldwide. A leader in sustainability, corporate philanthropy and employment opportunity, Walmart ranked first among retailers in Fortune Magazine's 2010 Most Admired Companies survey. Additional information about Walmart can be found by visiting www.walmartstores.com and on Twitter at http://Twitter.com/Walmartnews. Online merchandise sales are available at www.walmart.com and www.samsclub.com.

References

(1) "Centers for Medicare & Medicaid Services." Click on the "2011 Drug Plan Information - State Fact Sheets" under "Spotlights." September 2010
'/>"/>

SOURCE Wal-Mart Stores, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that agreement has been reached with ... the design of a pivotal, Phase 3 clinical ... the treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... , 17. September 2014 /PRNewswire/ ... HOLX ), hat heute die Markteinführung ... präanalytischen Probenverarbeitung, in Europa bekannt gegeben. ... vollautomatisierte Universalplattform zur Vereinfachung der präanalytischen ... ineffiziente und fehlerbehaftete Arbeitsschritte bei der ...
(Date:9/16/2014)... , Sept. 16, 2014 A study led ... has found the chemotherapy dose threshold below which male ... production. The study appears in September 17 edition of ... clarifying which patients are at highest risk for reduced ... eventually increase use of pre-treatment fertility preservation methods such ...
Breaking Medicine Technology:Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 3Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... Pressure and Triglycerides Also Observed , , NEW ORLEANS, ... ), Eli Lilly and Company (NYSE: LLY ), ... long-term, interim results from the DURATION-1 study that showed sustained ... systolic blood pressure and triglycerides, through two years of treatment ...
... June 7 New Phase II data presented today at ... show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) ... weekly, biweekly and monthly dosing. Reducing blood sugar is ... that affects over 250 million people worldwide. , ...
Cached Medicine Technology:Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 2Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 3Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 4Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 5Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 6Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 7Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 2Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 3
(Date:9/17/2014)... Tampa, FL (PRWEB) September 17, 2014 Tina ... ), is finishing up her chemotherapy but not her fight ... up for the Komen Florida Suncoast “Race for the Cure” ... “I registered for the Komen Race for the Cure because ... breast cancer,” Griffin said. , As part of her efforts, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Four ... eighth annual Wailea Tennis Fantasy Camp on ... Maui’s prestigious Wailea Tennis Club, with three-time grand slam ... returning to Wailea, Maui for her fifth year. , ... match play with Davenport, recently inducted into the International ...
(Date:9/17/2014)... September 17, 2014 A raucous childhood ... come together to form author Nancy Chovancek’s laughter-filled new ... is a collection of short stories that prove the ... fun. With a positive message of empowerment and resilience, ... is a proven author with two books under her ...
(Date:9/17/2014)... This September 18-20, 22 participating developmentally-disabled athletes ... three stage outdoor sporting event in non-profit World T.E.A.M. ... , Hosted at The Center for Discovery ... five participating teams coached by able-bodied athletes. For each ... provide expert guidance as well as technical assistance. Like ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Lee ... settlement industry, will be appearing on The Balancing Act® ... two September episodes. , The segment will premiere on ... on 'The Balancing Act® airing on Lifetime Television®' with ... of Asset Funding Corp. for over a decade and ...
Breaking Medicine News(10 mins):Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 3Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2
... Polyp Detection by Thirteen Percent, SAN DIEGO, ... in San Diego (DDW 2008), world-renowned gastroenterologist,Jerome D. ... which evaluated the efficacy of the Third Eye(TM) ... physicians to visualize,abnormalities in the colon., The ...
... near Mosul in 2003 , , WEDNESDAY, May 21 (HealthDay News) ... near Mosul, Iraq, in 2003 returned home with a debilitating ... , But doctors were only able to diagnose the condition, ... to reliably identify the problem, said the authors of a ...
... (Amex: QGP, QGP.WSA, QGP.WSB) ( http://www.QuantumMD.com ) ... plan. The Company,increased its employment base by 23% since ... ft. to 10,600 sq. ft., and has moved a,branch ... Doral (west,Miami), Florida., Susan Darby Guillama, Executive Vice ...
... MINNEAPOLIS, May 21 ACM today announced a ... development efforts on,providing next generation technology and services ... of healthcare today: commercial plans and,payers, and federal ... Development Gary Loeber has been,named EVP/General Manager for ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
... Calif., May 21 LUMEDX Corporation, a ... information systems,(CVIS), introduces software to manage data ... The Anticoagulation Module empowers clinicians,by making critical ... safety., For more information -- including ...
Cached Medicine News:Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 2Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 4Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 5Health News:Some Iraq War Vets Suffer Breathing Problems 2Health News:Some Iraq War Vets Suffer Breathing Problems 3Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: